Zentalis Pharmaceuticals (ZNTL) Research & Development (2022 - 2025)
Historic Research & Development for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $23.0 million.
- Zentalis Pharmaceuticals' Research & Development fell 3767.65% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.8 million, marking a year-over-year decrease of 4055.34%. This contributed to the annual value of $167.8 million for FY2024, which is 1151.01% down from last year.
- Per Zentalis Pharmaceuticals' latest filing, its Research & Development stood at $23.0 million for Q3 2025, which was down 3767.65% from $27.6 million recorded in Q2 2025.
- In the past 5 years, Zentalis Pharmaceuticals' Research & Development registered a high of $51.6 million during Q4 2023, and its lowest value of $23.0 million during Q3 2025.
- In the last 4 years, Zentalis Pharmaceuticals' Research & Development had a median value of $42.7 million in 2023 and averaged $40.5 million.
- Its Research & Development has fluctuated over the past 5 years, first soared by 2693.77% in 2023, then crashed by 4504.99% in 2025.
- Zentalis Pharmaceuticals' Research & Development (Quarter) stood at $40.6 million in 2022, then increased by 26.94% to $51.6 million in 2023, then tumbled by 36.05% to $33.0 million in 2024, then tumbled by 30.4% to $23.0 million in 2025.
- Its Research & Development stands at $23.0 million for Q3 2025, versus $27.6 million for Q2 2025 and $27.2 million for Q1 2025.